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Abstract
Tellurium compounds have shown several biological properties and recently the leishmanicidal effect of one
organotellurane was demonstrated. These findings led us to test the effect of the organotellurium compound RF07 on
Leishmania (Leishmania) chagasi, the agent of visceral leishmaniasis in Latin America. In vitro assays were performed in L. (L.)
chagasi-infected bone marrow derived macrophages treated with different concentrations of RF07. In in vivo experiments
Golden hamsters were infected with L. (L.) chagasi and injected intraperitoneally with RF07 whereas control animals
received either Glucantime or PBS. The effect of RF07 on cathepsin B activity of L. (L.) chagasi amastigotes was assayed
spectrofluorometrically using fluorogenic substrates. The main findings were: 1) RF07 showed significant leishmanicidal
activity against intracellular parasites at submicromolar concentrations (IC50 of 529.7626.5 nM), and the drug displayed 10-
fold less toxicity to macrophages (CC50 of 5,4266272.8 nM); 2) kinetics assays showed an increasing leishmanicidal action
of RF07 at longer periods of treatment; 3) one month after intraperitoneal injection of RF07 L. (L.) chagasi-infected hamsters
showed a reduction of 99.6% of parasite burden when compared to controls that received PBS; 4) RF07 inhibited the
cathepsin B activity of L. (L.) chagasi amastigotes. The present results demonstrated that the tellurium compound RF07 is
able to destroy L. (L.) chagasi in vitro and in vivo at concentrations that are non toxic to the host. We believe these findings
support further study of the potential of RF07 as a possible alternative for the chemotherapy of visceral leishmaniasis.
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Introduction
Leishmaniasis comprise a group of diseases whose etiological
agents are protozoan parasites of the Leishmania genus that cause
cutaneous, mucocutaneous and visceral leishmaniasis. According
to the World Health Organization there are currently 12 million
cases of leishmaniasis and 350 million people are at risk of
acquiring some form of the disease. Leishmania (Leishmania) chagasi is
the causative agent of visceral leishmaniasis (VL) in Latin America.
VL is the most severe form of the disease and affects 500,000
people worldwide. VL is a chronic, debilitating disease which has a
consumptive character, and may lead to death if untreated [1,2].
The first-line drugs used for treatment of leishmaniasis are
pentavalent antimonial compounds, while amphotericin B and
pentamidine are used as the second-line chemotherapy [3].
Miltefosine, originally developed as an anticancer agent, showed
good efficacy for treatment of visceral leishmaniasis in India and
cutaneous leishmaniasis in Colombia [4,5]. However, the use of
these compounds is limited by toxicity to the host and the
development of resistance by the parasites [3,6]. Furthermore,
dogs, the main reservoir of zoonotic VL in Latin America and
Mediterranean area, do not respond satisfactorily to drugs used for
human VL chemotherapy. For this reason the control of canine
visceral leishmaniasis has been based on the sacrifice of infected
animals that results in a serious problem for public health agents
and an ineffective reservoir control that contributes to disease
urbanization [7]. These issues have led to the search of new drugs
less toxic to VL patients and also active against canine VL. Several
compounds including synthetic, natural products extracted from
plants and marine sources have shown different degrees of efficacy
in the treatment of experimental VL [8–12].
During the last decade an increasing interest in the study of
tellurium compounds as chemotherapeutic agents has emerged.
There are two main classes of tellurium compounds which
comprise inorganic and organic derivatives that have shown
antimicrobial, antihelmintic, antioxidant, immunomodulatory and
Figure 1. Molecular structure of organotellurane RF07.
doi:10.1371/journal.pone.0048780.g001
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antitumoral properties [13–18]. Hypervalent organotellurium
compounds termed organotelluranes have also been studied as
potent inhibitors of cysteine proteases [14,19] and their effect on
systems associated to the activity of these enzymes has been
demonstrated. Thereby, the effect of organotelluranes in angio-
genesis, in the cytotoxicity on several cancer cell lineages, in the
induction of apoptosis in human HL-60 cells, as well as in the
inactivation of caspases leading to the protective effect of epilepsy
in rats was reported [20,21]. In Leishmania cathepsin B has been
found to be involved in parasite invasion and survival in
macrophages [22,23]. The inhibitory role of organotelluranes on
cathepsin B activity and recent demonstration that the organo-
tellurane RT01 destroyed promastigote and amastigote forms of L.
(L.) amazonensis [24] led us to test the leishmanicidal activity of the
organotellurane RF07 on L. (L.) chagasi. The present study
describes the effect of this tellurium compound on intracellular
amastigotes and Golden hamsters infected with L. (L.) chagasi.
Methods
Animals
Female BALB/c mice six to eight weeks old were obtained from
breeding stocks maintained at Universidade Federal de Sa˜o Paulo
(Sa˜o Paulo, Brazil) and eight-week-old male Golden hamsters were
acquired from Universidade de Campinas (Sa˜o Paulo, Brazil). This
study was carried out in strict accordance with the recommenda-
tions in the Guide for the Care and Use of Laboratory Animals of
the Brazilian National Council of Animal Experimentation
(http://www.cobea.org.br). The protocol was approved by the
Committee on the Ethics of Animal Experiments of the
Institutional Animal Care and Use Committee at the Federal
University of Sa˜o Paulo (Id # CEP 1295/10).
Parasites
The L. (L.) chagasi strain used (MHOM/BR/1972/LD) was
kindly provided by Dr. Jeffrey J. Shaw, Instituto Evandro Chagas
(Bele´m, Para´, Brazil) and maintained as amastigotes by inoculation
of Golden hamsters by the intraperitoneal route every 4 to 6 weeks
as previously described [25]. Two months after infection, the
animals were sacrificed and the spleens were homogenized and
centrifuged for isolation of amastigotes. The resulting pellet was
resuspended in phosphate buffered saline (PBS), centrifuged at
2506g for 5 min, the supernatant was centrifuged at 1,4006g for 5
minutes and the pellet was resuspended in PBS. The suspension
was agitated for 3 hours at room temperature and centrifuged at
1,4006g for 5 minutes. The final pellet contained purified
amastigotes essentially free of contamination by other cells and
macrophage debris. This pellet was resuspended in PBS,
amastigotes were counted in a hemocytometer and used to infect
macrophages or hamsters.
Hypervalent Tellurium Compound 4-{2-Chloro-3-
[chloromethylidene]-1-oxa-2-l4-telluraspiro[3.5]non-2-
yl}phenyl Methyl Ether (RF07)
The tellurium compound RF07 (molecular weight 427.5 g/mol)
(Figure 1) was synthesized by reaction of p-methoxyphenyl
tellurium with 1-ethynyl-1-cyclohexanol in benzene reflux as
previously described [26]. After preparation, the product RF07
was firstly purified by fractional crystallization and then re-purified
by re-crystallization for use in biological assays. Stock solutions
prepared in dimethylsulfoxide (DMSO) were diluted with PBS for
use in the in vitro and in vivo assays.
Effect of RF07 on L. (L.) chagasi-infected Macrophages
The activity of RF07 on intracellular amastigotes was evaluated
in mouse bone marrow derived macrophages infected with L. (L.)
chagasi. Bone marrow derived macrophages were generated from
bone marrow stem cells isolated from BALB/c mice [27]. Cells
were counted, added (86105) and cultured on glass coverslips
inserted in 24-well tissue culture plates containing RPMI 1640
medium buffered with 15 mM of HEPES, 20 mM of sodium
bicarbonate and supplemented with 1 mM of L-glutamine, 20% of
fetal calf serum (FCS) and 30% of L929 cell conditioned medium
(LCCM). Cultures were kept at 37uC in an atmosphere of air/
CO2 (95/5%). After 5 days, the medium was changed for RPMI
containing 10% of FCS and macrophages were infected at a
multiplicity of 5 amastigotes per macrophage. After 24 hours,
infected cultures were treated with different drug concentrations
(350 to 2,000 nM) for 3 days. The coverslips were fixed with
methanol, stained with hematoxylin-eosin (HE) and intracellular
Figure 2. Activity of RF07 on L. (L.) chagasi-infected macro-
phages. Mouse bone marrow derived macrophages were infected with
amastigotes of L. (L.) chagasi, treated with the drugs for 3 days and the
infection index was estimated. *P,0.001 compared to control.
doi:10.1371/journal.pone.0048780.g002
Figure 3. Kinetics of RF07 leishmanicidal activity on L. (L.)
chagasi-infected macrophages. Macrophages were infected with
amastigotes of L. (L.) chagasi, treated with the drugs for 3, 5 and 7 days
and the infection index was calculated after each period. *P,0.001
compared to control.
doi:10.1371/journal.pone.0048780.g003
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amastigotes were counted. Results are expressed by the infection
index, obtained by multiplying the percentage of infected
macrophages by the average number of amastigotes per macro-
phage. At least 200 macrophages were scored in each 3 coverslips.
For kinetics experiments L. (L.) chagasi-infected macrophages were
treated with 750 nM of RF07 for 3, 5 and 7 days and the infection
index was evaluated. Glucantime (Sanofi-Aventis, Brazil, 300 mg/
ml, 81 mg/ml SbV) was used as standard drug for treatment of L.
(L.) chagasi amastigotes.
Cytotoxicity Assays
RF07 cytotoxicity to macrophages was tested by a MTT
micromethod described previously [28] after incubation of bone
marrow derived macrophages with 350 nM to 10 mM of RF07 for
3 days. Macrophages were also incubated with the highest
concentration of DMSO used for RF07 solubilization (0.04%).
The formation of formazan was measured by adding 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT;
Molecular Probes, Eugene, OR, USA) 0.5 mg/ml and incubation
of the cultures at 37uC in the dark. After 4 hours the medium was
removed, 200 ml of DMSO was added per well and the
absorbance was measured using an ELISA reader at 540 nm
(Labsystems Multiskan).
Antileishmanial in vivo Activity
In order to evaluate the in vivo leishmanicidal activity of RF07
male Golden hamsters 8 weeks-old were infected by intraperito-
neal route with 16108 L. (L.) chagasi amastigotes freshly isolated
from spleen of infected hamsters. One month after infection, the
animals were randomly separated in 5 groups of 6 hamsters each.
Treated animals received daily intraperitoneal doses of either
52.76 mmol/kg/day of Glucantime or 0.323 mmol/kg/day,
0.646 mmol/kg/day or 1.292 mmol/kg/day of RF07 for 15 days.
Control group received the same number of injections of PBS.
One month after treatment the animals were sacrificed and the
parasite burden was evaluated in spleen and liver by limiting
dilution method, as previously described [29].
Toxicity Assays for Golden Hamsters
Serum concentrations of albumin, transaminases and creatinine
were determined in Golden hamsters 15 days after the end of
treatment, using sets of commercial reagents (Doles Reagentes e
Equipamentos para Laborato´rios, Ltda, Brazil).
Assays of Cathepsin Activity in L. (L.) chagasi Amastigote
Lysates
Cathepsin activities were monitored with the fluorogenic
substrates Z-Phe-Arg-AMC (for all cathepsins) and Z-Arg-Arg-
AMC (for cathepsin B) using 10 ml of L. (L.) chagasi amastigote cell
lysate (16109 amastigotes disrupted in 100 ml PBS), 1 ml of four-
component buffer comprised of 25 mM acetic acid, 25 mM MES
(4-morpholineethanesulfonic acid), 75 mM Tris, 25 mM glycine,
pH 5.0, 5 mM dithiothreitol (DTT), 10 mM of each fluorogenic
substrate and 50 mM of RF07. The effect of RF07 on the parasite
enzyme activity was tested by incubation of the L. (L.) chagasi lysate
with RF07 for 2 minutes in buffer solution at 37uC; the fluorogenic
substrate was then added and fluorescence of the released
fluorophore, 7-amino-4-methylcoumarine (AMC), was measured
over time. The remaining enzyme activities were determined and
expressed as a percentage of the activity of the control experiment.
Parasite lysate was also incubated with 6,4 mM of the fluorogenic
substrate Abz-Gly-Ile-Val-Arg-Ala-Lys(Dnp)-OH (Sigma, St.
Louis, MO, USA), specific for cathepsin B [30], in the presence
of either increasing concentrations of RF07 or CA074, a specific
inhibitor of cathepsin B. The cathepsin activity was monitored
spectrofluorometrically using the fluorogenic substrates on a
Hitachi F-2000 spectrofluorometer equipped with a thermostated
cell holder. The fluorescence excitation (lEx) and emission (lEm)
wavelengths, for the fluorescence of AMC, were set at 380 nm and
460 nm, respectively, while the parameters for the fluorescence of
Abz-peptide fragments resulting from the Abz-Gly-Ile-Val-Arg-
Ala-Lys(Dnp)-OH hydrolysis were set at lex = 320 and
lem = 420 nm.
Statistical Analysis
ANOVA and Student’s t test were used to determine the
statistical differences between groups and P values ,0.05 or lower
were considered statistically significant. IC50, IC90, CC50 and
CC90 values were determined by GraphPad Prism, version 5.0.
Results
Leishmanicidal Activity of RF07 on L. (L.) chagasi-infected
Macrophages
Mouse bone marrow derived macrophages infected with L. (L.)
chagasi amastigotes for 24 hours were treated with different
concentrations of RF07 ranging from 350 to 2,000 nM. Treat-
ment of infected cultures with Glucantime was used as a positive
control. Three days after incubation, infected macrophages were
fixed and stained for parasite counts and determination of the
infection index. A significant, dose-dependent decrease in macro-
phage infection was observed with an inhibition of 85% for
750 nM of RF07 (IC50 of 529.7626.5 nM and IC90 of
1,7486335 nM) (Figure 2). The cytotoxicity of RF07 on
macrophages was evaluated by the MTT method and 96 h after
treatment a CC50 of 5,3996290 nM and a CC90 of
17,90561.050 nM were determined. It is still important to
mention, as expected from the chemical stability of the
hypervalent tellurium compounds [14,15], that 3 different batches
of RF07 were tested and no differences in their leishmanicidal
effect were observed (data not shown). Leishmanicidal effect on
intracellular amastigotes was also observed in the presence of
Glucantime tested in a range of 15–600 mg/ml and IC50 and
Figure 4. Treatment of L. (L.) chagasi-infected hamsters with
RF07. Spleen parasite load of L. (L.) chagasi-infected hamsters treated
with either different concentrations of RF07 or Glucantime was
determined by the limiting dilution method one month after end of
the treatment. *P,0.001 compared to control.
doi:10.1371/journal.pone.0048780.g004
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IC90 values were 12.62 and 113.5 mg/ml, respectively (corre-
sponding to 3364.1 mM and 296635 mM).
Kinetics of L. (L.) chagasi destruction was performed by use of
RF07 at 750 nM for 3, 5 and 7 days. An inhibition of 85%, 92.4%
and 95.7% on L. (L.) chagasi infection was observed 3, 5 and 7 days
after treatment, respectively (Figure 3). Glucantime also exhibited
a significant leishmanicidal effect (80%, 84.9% and 91.5%), but
was toxic to macrophages after 5 and 7 days, while RF07 did not
show macrophage toxicity in any period of treatment (data not
shown).
Effect of RF07 on Hamsters Infected with L. (L.) chagasi
Golden hamsters infected with L. (L.) chagasi and treated with
either 0.323 mmol/kg/day, 0.646 mmol/kg/day or 1.292 mmol/
kg/day of RF07 displayed a significant reduction of spleen parasite
load of 92.5%, 92.6% and 99.6%, respectively (Figure 4). Control
groups that received 52.76 mmol/kg/day of Glucantime showed a
reduction of 97.5% compared to untreated controls. Similar
results were observed in liver parasite burden.
Evaluation of hepato and nephrotoxicity of RF07 by detection
of serum levels of albumin, transaminases and creatinine showed
no statistically significant alterations between non-treated and
treated groups (Figure 5).
Effect of RF07 on Proteolytic Activity of L. (L.) chagasi
Amastigotes
In order to investigate the possible inhibitory action of RF07 on
L. (L.) chagasi cysteine proteases, spectrofluorometric assays were
performed by incubation of cathepsin-like cysteine protease
substrates with extracts of L. (L.) chagasi amastigotes in the
presence of the reducing agent DTT. Although a dose-dependent
inhibition of L. (L.) chagasi proteolytic activity by RF07 was
observed by using both fluorogenic substrates (Figure 6A), a value
of IC50 ten times higher was obtained on Z-Arg-Arg-AMC
hydrolysis (IC50 of 450 mM and 41 mM for Z-Arg-Arg-AMC and
Z-Phe-Arg-AMC, respectively). However, at lower concentrations
RF07 inhibited the activity of L. (L.) chagasi extract on a most
specific substrate for cathepsin B-like (Figure 6B). Inhibition of L.
(L.) chagasi proteolytic activity by CA074 was also observed
(Figure 6C) and the calculated IC50 values for RF07 and CA074
were not significantly different (4.4760.13 mM and
2.4160.15 mM, respectively). These results strongly suggest that
RF07 inhibits L. (L.) chagasi cathepsin B-like activity.
Discussion
The present study focused on the in vitro and in vivo activity of
the organotellurane RF07 on L. (L.) chagasi. Our data showed the
Figure 5. Toxicity evaluation in L. (L.) chagasi-infected hamster after treatment with RF07. Serum concentrations of albumin (A),
transaminases (B) and creatinine (C) in L. (L.) chagasi-infected hamsters 15 days after treatment with either RF07 or Glucantime. The reference values
are: albumin: 3.2–4.3 g/dl; transaminases: ALT: 53–202 UI/L, AST: 28–107 UI/L; creatinine: 0.5–0.6 mg/dl.
doi:10.1371/journal.pone.0048780.g005
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leishmanicidal activity of RF07 against intracellular amastigotes,
whereas the drug displayed 10-fold less toxicity to macrophages.
Although similar leishmanicidal effect was observed with Glucan-
time, significantly higher concentrations of the antimonial were
necessary to destroy L. (L.) chagasi amastigotes. The leishmanicidal
activity of RF07 is comparable to that reported for several
compounds tested against visceralizing Leishmania species like the
2,4,6-trisubstitued pyrimidines and 1,3,5-triazines, tamoxifen and
several drugs tested by high-throughput screening such as
naloxonazine and others not identified [31–34]. However, higher
concentrations of these compounds were used to destroy L. (L.)
chagasi, whereas RF07 exerted an effective leishmanicidal effect at
submicromolar concentrations. Among other tellurium com-
pounds previously tested against Leishmania only the organotellur-
ane RT01 exhibited an in vitro and in vivo antileishmanial property
[24]. Neverthless, this compound was tested on a cutaneous
species of Leishmania, impairing the comparison with RF07 data.
The efficiency of RF07 in destroying L. (L.) chagasi in vivo was
also demonstrated. Treatment of L. (L.) chagasi-infected hamsters
with RF07 led to a significant reduction of parasite load in animal
spleens (92.5%, 92.6%, and 97.5%, respectively, with
0.323 mmol/kg/day, 0.646 mmol/kg/day, and 1.292 mmol/kg/
day of RF07). Although the reduction of parasite burden in L. (L.)
chagasi-infected hamsters treated with RF07 was similar to that
observed with Glucantime, the antimonial compound was used in
40 times higher concentration. These data support literature
reports that show the high concentrations of Glucantime required
for a curative effect in patients suffering from visceral leishmaniasis
that result in the toxicity often observed among these patients [35].
On the other hand, treatment with RF07 did not result in toxicity
in L. (L.) chagasi-infected hamsters as demonstrated by hepatic and
renal assays after treatment with the drug according to reported
reference values [36]. The leishmanicidal effect of RF07 on L. (L.)
chagasi-infected hamsters is also comparable to that obtained with
tamoxifen, whereas it showed higher effectiveness than 2,4,6-
trisubstitued pyrimidines and 1,3,5-triazines that reduced the
parasite burden by 48 to 52%. Moreover, in both assays infected
hamsters received significantly higher drug concentrations than
those used for treatment with RF07 [33,34].
At this stage, our data pointed out the use of RF07 as a
leishmanicidal agent. However, it is important to consider the
possible occurrence of cross-resistance of RF07 and Sb-resistant
strains. This hypothesis is based on the mechanisms of action and
resistance of antimonial-based compounds toward Leishmania
Figure 6. Effect of RF07 on proteolytic activity of L. (L.) chagasi amastigotes. A - Fluorogenic substrates with different specificities for
cathepsin-like proteases were incubated with extracts of L. (L.) chagasi amastigotes in the presence of DTT and increasing concentrations of RF07, as
indicated. B and C - Fluorogenic substrate specific for cathepsin B-like proteases was incubated with extracts of L. (L.) chagasi in presence of
increasing concentrations of either RF07 (B) or CA074 (C).
doi:10.1371/journal.pone.0048780.g006
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which involves the reactions of the Sb(III) species with biothiols
[38], similar to the known particular reactivity of telluranes
towards thiols [19,37,39].
Literature evidence that organotelluranes inhibit cysteine
protease activity [19,37] led us to test the effect of RF07 on L.
(L.) chagasi protease activity. Our previous spectrofluorometric
assays indicated an apparent inhibition of parasite cathepsin L.
However, cloning of the gene encoding cathepsin B of L. (L.)
chagasi and analysis of predicted amino acid sequence of this
enzyme showed a replacement of serine 331 by a glycine residue
which results in a low activity of this enzyme toward the synthetic
peptide substrate Z-Arg-Arg-AMC and favours the hydrolysis of
the substrate Z-Phe-Arg-AMC [22]. These data led us to test a
more specific substrate for cathepsin B whose hydrolysis was
significantly inhibited in presence of low concentrations of RF07.
The involvement of L. (L.) chagasi cathepsin B with mouse
macrophage infection and parasite survival has been already
demonstrated [22,23]. Thus, our findings may indicate a
relationship between the leishmanicidal effect of RF07 and L.
(L.) chagasi cathepsin B inhibition. However, other relevant targets
may account for the leishmanicidal effect of the drug and they are
now under investigation. Tellurium compounds have exhibited
immunomodulatory properties [15]. Studies on the possible
immunomodulatory effect of RF07 in treated L. (L.) chagasi-
infected hamsters are currently in progress.
In conclusion, the effectiveness of RF07 in destroying L. (L.)
chagasi in vitro and in vivo at concentrations non toxic to the host
opens perspectives to explore the potential of RF07 as an
additional option for the chemotherapy of visceral leishmaniasis,
encouraging us to extend these studies for treatment of canine
visceral leishmaniasis.
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